Compare Aurobindo Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs WOCKHARDT - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA WOCKHARDT AUROBINDO PHARMA/
WOCKHARDT
 
P/E (TTM) x 10.0 -19.4 - View Chart
P/BV x 1.8 0.9 216.3% View Chart
Dividend Yield % 0.6 0.0 12,621.2%  

Financials

 AUROBINDO PHARMA   WOCKHARDT
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
WOCKHARDT
Mar-18
AUROBINDO PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs8301,012 82.0%   
Low Rs527532 99.2%   
Sales per share (Unadj.) Rs333.9355.9 93.8%  
Earnings per share (Unadj.) Rs40.4-60.3 -67.0%  
Cash flow per share (Unadj.) Rs51.8-46.8 -110.7%  
Dividends per share (Unadj.) Rs2.500.01 25,000.0%  
Dividend yield (eoy) %0.40 28,433.8%  
Book value per share (Unadj.) Rs237.1257.8 92.0%  
Shares outstanding (eoy) m585.91110.63 529.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.02.2 93.7%   
Avg P/E ratio x16.8-12.8 -131.3%  
P/CF ratio (eoy) x13.1-16.5 -79.4%  
Price / Book Value ratio x2.93.0 95.6%  
Dividend payout %6.20 -37,341.1%   
Avg Mkt Cap Rs m397,56985,379 465.7%   
No. of employees `00017.96.3 285.5%   
Total wages/salary Rs m25,8499,371 275.8%   
Avg. sales/employee Rs Th10,956.96,295.0 174.1%   
Avg. wages/employee Rs Th1,447.71,498.3 96.6%   
Avg. net profit/employee Rs Th1,324.3-1,066.3 -124.2%   
INCOME DATA
Net Sales Rs m195,63639,369 496.9%  
Other income Rs m1,5531,202 129.2%   
Total revenues Rs m197,18940,571 486.0%   
Gross profit Rs m39,51918 215,953.0%  
Depreciation Rs m6,6801,495 446.7%   
Interest Rs m2,6262,555 102.8%   
Profit before tax Rs m31,767-2,830 -1,122.7%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881-3,582 24.6%   
Tax Rs m7,269257 2,828.2%   
Profit after tax Rs m23,645-6,669 -354.6%  
Gross profit margin %20.20 43,457.6%  
Effective tax rate %22.9-9.1 -251.9%   
Net profit margin %12.1-16.9 -71.4%  
BALANCE SHEET DATA
Current assets Rs m153,64533,796 454.6%   
Current liabilities Rs m120,42926,917 447.4%   
Net working cap to sales %17.017.5 97.2%  
Current ratio x1.31.3 101.6%  
Inventory Days Days13579 170.4%  
Debtors Days Days6489 71.4%  
Net fixed assets Rs m103,90939,664 262.0%   
Share capital Rs m586553 105.9%   
"Free" reserves Rs m138,32227,968 494.6%   
Net worth Rs m138,90828,522 487.0%   
Long term debt Rs m1,80021,731 8.3%   
Total assets Rs m264,54481,620 324.1%  
Interest coverage x13.1-0.1 -12,181.2%   
Debt to equity ratio x00.8 1.7%  
Sales to assets ratio x0.70.5 153.3%   
Return on assets %9.9-5.0 -197.0%  
Return on equity %17.0-23.4 -72.8%  
Return on capital %23.8-7.7 -310.6%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,3169,807 992.3%   
Fx outflow Rs m40,5891,789 2,269.3%   
Net fx Rs m56,7278,019 707.5%   
CASH FLOW
From Operations Rs m16,220684 2,370.0%  
From Investments Rs m-28,7686,302 -456.5%  
From Financial Activity Rs m19,191-7,695 -249.4%  
Net Cashflow Rs m6,656-664 -1,002.5%  

Share Holding

Indian Promoters % 54.1 74.5 72.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 2.3 345.7%  
FIIs % 27.7 7.7 359.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.2 15.4 66.2%  
Shareholders   69,601 67,757 102.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  DIVIS LABORATORIES  ALEMBIC LTD  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Lower, LIC IPO, Stocks in Focus, and Top Cues to Track Today(Pre-Open)

Indian share markets ended on a negative note yesterday, tracking weakness in global markets owing to coronavirus outbreak.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

How to Identify a Market Rebound(Fast Profits Daily)

Mar 27, 2020

This very useful indicator can spot a market bottom.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Apr 8, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - TTK HEALTHCARE COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS